Celgene Corp.’s June 29 tie-up with CAR-T pioneer Juno Therapeutics Inc. may have set a new high for upfront payments, according to the Strategic Transactions database, but the collaboration gives it first pick from a hotly anticipated pipeline and came through a competitive process, Celgene executives told “The Pink Sheet.”
“We really feel this is reflective of the value of the collaboration and is consistent with the market now in immuno-oncology,” Robert Hershberg, Celgene’s senior VP of immuno-oncology, said in an interview